Article
Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study.
Leukemia & lymphoma - 1 Sept 2011
Bengió Raquel M, Riva Maria E, Moiraghi Beatriz, Lanari Emilio, Milone Jorge, Ventriglia Veronica, Bullorsky Eduardo, Tezanos Pinto Miguel de, Murro Hector, Bianchini Michele, Larripa Irene
Abstract excerpt
In imatinib-treated patients with chronic myeloid leukemia (CML), BCR-ABL mutations are the most common mechanism of resistance. Here we report the first multicenter Argentinean study investigating mutations in those patients with CML who fail or lose response to imatinib, with or without previous interferon treatment. Point mutations were detected in 36 of 154 patients by direct sequencing. In our series, the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.